

SGLT2 Benefits Vs. Risks

Adapted from Cardiac benefits in Diabetes Therapy: Comparing SGLT2 Inhibitors and GLP-1 Agonists

By Samuel Grossman, BS Pharm, PharmD, CDE, FADE

Benefits	Risks
A1c reduction 0.5-1%	Hypotension: increase risk with diuretics
CV benefits	Dehydration: increase risk with diuretics, low BP, renal disease, age
30-40% reduction in albuminuria	Genital mycotic/urinary tract infections
BP reduction 2mmHg systolic & 5mmHg diastolic	Euglycemic diabetes ketoacidosis
Low risk hypoglycemia	Increased amputation risk: canagliflozin
Weight loss	Increased fracture risk: canagliflozin, dapagliflozin. ^{2,3}

References:

- <https://academic.oup.com/eurheartj/article/37/19/1526/2240594/Heart-failure-outcomes-with-empagliflozin-in> Accessed Jan 2018
- [http://www.thelancet.com/journals/landia/article/PIIS2213-8587\(14\)70227-X](http://www.thelancet.com/journals/landia/article/PIIS2213-8587(14)70227-X) accessed Jan 2018
- <https://www.fda.gov/Drugs/DrugSafety/ucm461449.htm> accessed Jan 2018